抗レウマティック薬のチラリティ
W F Kean1, C J Lock, H E Howard-Lock
1Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
Lancet (London, England)
|December 21, 1991
まとめ
チラル薬は,エナンティオマーとして存在し,さまざまな生物学的効果を持つことができます. 臨床医は,これらのリスクに対するより高い認識を必要とし,研究および臨床試験における単一のエナチオメールの使用を提唱します.
科学分野:
- 薬用化学 薬用化学について
- 薬理学 薬理学とは
- クリニカル・プラクティス クリニカル・プラクティス
背景:
- 薬剤分子のキラリティは,異なる生物学的活動を持つエナンティオマーにつながる可能性があります.
- 臨床医は,しばしばキラル薬物使用に関連するリスクの認識が欠けている.
- 異なるエナチオマーは,異なる有効性および毒性プロフィールを表す可能性があります.
研究 の 目的:
- クリニカル・プラクティスにおけるキラル分子の使用に起因する潜在的な問題を強調する.
- 薬剤の有効性および毒性に対するキラリティの影響について議論する.
- 研究および臨床環境において単一のエナンティオメアの使用を推奨する.
主な方法:
- キラリティを記述するための化学的慣例についての議論.
- チラリティが抗レウマティック薬に与える影響を示す例を紹介した.
- エナンティオメアの生物学的活動と臨床的影響のレビュー.
主要な成果:
- 薬物のエナチオメアは,著しく異なる生物学的活性を持つことができます.
- チラリティは,薬剤の治療効果と潜在的な毒性の両方に影響を与えます.
- キラルリスクに関する臨床医の意識の欠如は重要な問題である.
結論:
- 単一のエナチオマーは,生物学的実験で好ましく使用すべきである.
- 臨床試験は,予測可能な結果を確保するために,単一のエナティオメール薬に重点を置くべきである.
- 薬物キラリティに関する意識の向上と教育は,患者の安全にとって極めて重要です.
さらに関連する動画
07:15Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
07:11Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis
Published on: May 23, 2025
関連する概念動画
01:16Antihypertensive Drugs: Action of Diuretics
Diuretics are antihypertensive drugs used to treat hypertension resulting from sodium and water retention. Sodium, vital for fluid balance and nerve or muscle function, is regulated by the kidneys through millions of nephrons. Blood enters nephrons via afferent arterioles, which branch into capillaries called glomeruli. These filter blood plasma, allowing water and solutes, like sodium ions, to pass through capillary walls into Bowman's capsule. The filtrate then flows through various tubules...
01:15Antihypertensive Drugs: Thiazide-Class Diuretics
Thiazide diuretics are sulfonamide derivatives featuring a benzothiadiazine ring system in their molecular structure. Based on this structure, thiazide diuretics can be categorized into two groups: thiazide-type and thiazide-like diuretics. Thiazide-type diuretics, including hydrochlorothiazide and chlorothiazide, consist of a benzothiadiazine backbone with an attached sulfonamide group. Thiazide-like diuretics, such as chlorthalidone and indapamide, lack the thiazide ring but demonstrate...
01:17Antihypertensive Drugs: Action of β1 Blockers
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
01:25Antihypertensive Drugs: Direct Renin Inhibitors
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms: